Mavacamten
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Hypertrophic Cardiomyopathy
Conditions
Obstructive Hypertrophic Cardiomyopathy
Trial Timeline
Jul 24, 2024 → Nov 30, 2026
NCT ID
NCT06146660About Mavacamten
Mavacamten is a pre-clinical stage product being developed by Bristol Myers Squibb for Obstructive Hypertrophic Cardiomyopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06146660. Target conditions include Obstructive Hypertrophic Cardiomyopathy.
What happened to similar drugs?
20 of 20 similar drugs in Obstructive Hypertrophic Cardiomyopathy were approved
Approved (20) Terminated (2) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07361289 | Pre-clinical | Recruiting |
| NCT07004972 | Approved | Recruiting |
| NCT07383025 | Pre-clinical | Recruiting |
| NCT06146660 | Pre-clinical | Recruiting |
| NCT06338202 | Pre-clinical | Completed |
| NCT06551129 | Pre-clinical | Recruiting |
| NCT06549608 | Pre-clinical | Active |
| NCT06112743 | Approved | Active |
| NCT07107373 | Pre-clinical | Active |
| NCT05939700 | Pre-clinical | Recruiting |
| NCT06023186 | Pre-clinical | Recruiting |
| NCT07168655 | Pre-clinical | Completed |
| NCT05719805 | Phase 1 | Completed |
| NCT05582395 | Phase 3 | Completed |
| NCT05414175 | Phase 3 | Completed |
| NCT05362045 | Phase 1 | Completed |
| NCT04766892 | Phase 2 | Completed |
| NCT03723655 | Phase 2/3 | Completed |
| NCT03496168 | Phase 2 | Completed |
Competing Products
20 competing products in Obstructive Hypertrophic Cardiomyopathy